James R Jett

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Screening for lung cancer: current status and future directions: Thomas A. Neff lecture
    James R Jett
    Mayo Clinic, Rochester, MN 55905, USA
    Chest 125:158S-62S. 2004
  2. ncbi request reprint Limitations of screening for lung cancer with low-dose spiral computed tomography
    James R Jett
    Thoracic Diseases and Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:4988s-4992s. 2005
  3. ncbi request reprint Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition)
    James R Jett
    Division of Pulmonary Medicine and Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Chest 132:266S-276S. 2007
  4. doi request reprint Commentary: CT screening for lung cancer--caveat emptor
    James R Jett
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncologist 13:439-44. 2008
  5. ncbi request reprint Guidelines on treatment of stage IIIB non-small cell lung cancer
    James R Jett
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Chest 123:221S-225S. 2003
  6. ncbi request reprint Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group
    James R Jett
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 97:2498-503. 2003
  7. ncbi request reprint Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials
    Sumithra J Mandrekar
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Thorac Oncol 1:556-63. 2006
  8. ncbi request reprint Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer
    Steven E Schild
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 59:943-51. 2004
  9. doi request reprint Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study
    Alan H Bryce
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Clin Oncol 33:353-7. 2010
  10. ncbi request reprint Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2349-54. 2005

Detail Information

Publications76

  1. ncbi request reprint Screening for lung cancer: current status and future directions: Thomas A. Neff lecture
    James R Jett
    Mayo Clinic, Rochester, MN 55905, USA
    Chest 125:158S-62S. 2004
    ..Last, there is a brief discussion of some promising future strategies, with emphasis and data from studies presented at this Aspen Lung Conference...
  2. ncbi request reprint Limitations of screening for lung cancer with low-dose spiral computed tomography
    James R Jett
    Thoracic Diseases and Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:4988s-4992s. 2005
    ....
  3. ncbi request reprint Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition)
    James R Jett
    Division of Pulmonary Medicine and Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Chest 132:266S-276S. 2007
    ..To develop evidence-based guidelines on best available treatment options for patients with stage IIIB non-small cell lung cancer (NSCLC)...
  4. doi request reprint Commentary: CT screening for lung cancer--caveat emptor
    James R Jett
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Oncologist 13:439-44. 2008
  5. ncbi request reprint Guidelines on treatment of stage IIIB non-small cell lung cancer
    James R Jett
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Chest 123:221S-225S. 2003
    ..Treatment of stage IIIB due to malignant pleural effusion is addressed in the section that deals with stage IV disease...
  6. ncbi request reprint Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group
    James R Jett
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 97:2498-503. 2003
    ..The objective of this study was to test the response rate and toxicity of alternating chemotherapy in previously untreated patients with extensive-stage small cell lung carcinoma (SCLC)...
  7. ncbi request reprint Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials
    Sumithra J Mandrekar
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Thorac Oncol 1:556-63. 2006
    ..This pooled analysis was performed to examine the impact of pretreatment factors on severe (grade 3 or higher) adverse events (AE) in patients with advanced stage non-small cell lung cancer (NSCLC)...
  8. ncbi request reprint Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer
    Steven E Schild
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 59:943-51. 2004
    ..This Phase III study was performed to determine whether twice-daily (b.i.d.) radiotherapy (RT) resulted in better survival than once-daily (q.d.) RT for patients with limited-stage small-cell lung cancer (LD-SCLC)...
  9. doi request reprint Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study
    Alan H Bryce
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Am J Clin Oncol 33:353-7. 2010
    ..Previous studies have suggested improved outcomes with a topoisomerase I inhibitor in combination with a platinum agent...
  10. ncbi request reprint Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2349-54. 2005
    ..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial...
  11. ncbi request reprint The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:363-8. 2007
    ....
  12. ncbi request reprint The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly
    Steven E Schild
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Clin Oncol 21:3201-6. 2003
    ..No difference in survival was identified between the two arms. This secondary analysis was performed to examine the relationship between patient age and outcome...
  13. ncbi request reprint Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers
    Rebecca M Lindell
    Department of Radiology, Mayo Clinic, Charlton 2 290, 200 1st Street SW, Rochester, MN 55905, USA
    Radiology 242:555-62. 2007
    ....
  14. ncbi request reprint Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer
    Yolanda I Garces
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 67:995-1001. 2007
    ..The primary goal was to identify the maximum tolerable dose (MTD) of thoracic radiation therapy (TRT) that can be given with chemotherapy and amifostine for patients with limited-stage small-cell lung cancer (LSCLC)...
  15. ncbi request reprint Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening
    Cynthia O Townsend
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 103:2154-62. 2005
    ..Perhaps, recommendations from multiple cancer screenings may promote smoking abstinence among individuals at high risk for lung carcinoma...
  16. doi request reprint Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423
    Cheng E Chee
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:2382-9. 2010
    ..We conducted a trial to confirm the efficacy and to assess the tolerability of this chemotherapy combination...
  17. ncbi request reprint Lung cancer screening with CT: Mayo Clinic experience
    Stephen J Swensen
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Radiology 226:756-61. 2003
    ..To evaluate a large cohort of patients at high risk for lung cancer by using screening with low-dose spiral computed tomography (CT) of the chest...
  18. pmc Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials
    Nathan R Foster
    Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 115:2721-31. 2009
    ....
  19. pmc 5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size
    Rebecca M Lindell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Chest 136:1586-95. 2009
    ..The purpose of this study was to document the growth of lung cancers detected in high-risk participants receiving annual screening chest CT scans...
  20. doi request reprint Development of a multivariate model to predict the likelihood of carcinoma in patients with indeterminate peripheral lung nodules after a nondiagnostic bronchoscopic evaluation
    Jesse S Voss
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Hum Pathol 45:41-7. 2014
    ..78). These results suggest that this multivariate model including test results and clinical features may be useful following a nondiagnostic bronchoscopic examination. ..
  21. ncbi request reprint A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials
    Sumithra J Mandrekar
    Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 107:781-92. 2006
    ....
  22. ncbi request reprint Effectiveness of smoking cessation self-help materials in a lung cancer screening population
    Matthew M Clark
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    Lung Cancer 44:13-21. 2004
    ..Clearly, more investigation is warranted into how to tailor smoking interventions for cancer screening participants...
  23. ncbi request reprint Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 26:441-7. 2003
    ..However, the relatively mild toxicity profile observed in this trial suggests that this regimen might remain an option for patients at increased risk for myelosuppression or with a poor performance status...
  24. ncbi request reprint Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 29:246-51. 2006
    ..To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC)...
  25. pmc Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study
    Ping Yang
    College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Thorac Oncol 4:479-85. 2009
    ....
  26. ncbi request reprint CT screening for lung cancer: five-year prospective experience
    Stephen J Swensen
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Radiology 235:259-65. 2005
    ..To report results of a 5-year prospective low-dose helical chest computed tomographic (CT) study of a cohort at high risk for lung cancer...
  27. ncbi request reprint Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution
    Karin F Giordano
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lung Cancer 49:209-15. 2005
    ....
  28. doi request reprint Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis
    Fabien Maldonado
    Division of Pulmonary and Critical Care Medicine, Rochester, MN 55905, USA
    Chest 138:1295-302. 2010
    ..We proposed to assess this risk using a quantitative volumetric CT scan analysis...
  29. pmc Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report
    Farrah J Mateen
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Psychooncology 17:721-5. 2008
    ..Patients with schizophrenia sometimes receive substandard medical care. This study explored such disparities among lung cancer patients with underlying schizophrenia...
  30. ncbi request reprint Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis
    Adam Svobodnik
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1024-30. 2004
    ..To present the results of a quality-of-life (QOL) assessment performed with the current version of the Lung Cancer Symptom Scale (LCSS) questionnaire in a large single-institutional data set of 650 patients with lung cancer...
  31. ncbi request reprint The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules
    Craig E Daniels
    Division of Pulmonary and Critical Care Medicine, Desk East 18, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Chest 131:255-60. 2007
    ..Our purpose was to determine the sensitivity of FDG-PET to detect pulmonary carcinoid tumors...
  32. ncbi request reprint Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer
    Steven E Schild
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 54:370-8. 2002
    ..This Phase III study was performed to determine whether chemotherapy plus b.i.d. or q.d. radiotherapy (RT) resulted in superior survival for patients with Stage III non-small-cell lung cancer (NSCLC)...
  33. ncbi request reprint Advances in chemotherapy of non-small cell lung cancer
    Julian R Molina
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Chest 130:1211-9. 2006
    ....
  34. doi request reprint Fluorescence in situ hybridization testing algorithm improves lung cancer detection in bronchial brushing specimens
    Jesse S Voss
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Am J Respir Crit Care Med 181:478-85. 2010
    ..However, the sensitivity of cytology is suboptimal, especially for peripheral lesions less than 2 cm in diameter...
  35. pmc Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials
    Nathan R Foster
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota
    Cancer 117:1262-71. 2011
    ....
  36. ncbi request reprint Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population
    Rebecca M Lindell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    AJR Am J Roentgenol 185:126-31. 2005
    ..The objective of our study was to retrospectively review the PET results of non-small cell lung carcinomas detected on screening chest CT in a high-risk population...
  37. ncbi request reprint Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis
    Fabien Maldonado
    Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Pulm Med 16:315-20. 2010
    ....
  38. ncbi request reprint Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Cynthia X Ma
    Department of Oncology and Medicine, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5929-37. 2005
    ..A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naïve patients with non-small-cell lung cancer...
  39. ncbi request reprint Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group
    Grace K Dy
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Thorac Oncol 1:211-7. 2006
  40. ncbi request reprint Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma
    Brad E Wilcox
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lung Cancer 10:244-8. 2009
    ..Recent studies have examined the use of integrated CT-positron emission tomography (PET) for staging patients...
  41. ncbi request reprint Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002
    Antonio L Visbal
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 78:209-15; discussion 215. 2004
    ..Most of the reports are limited to selected groups of patients. The magnitude of gender effect on NSCLC survival across disease stage, tumor histology, and therapies needs to be further characterized...
  42. ncbi request reprint Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:9113-9. 2005
    ..To answer the question, "should elderly non-small-cell lung cancer patients be offered elderly-specific trials?"..
  43. ncbi request reprint Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 11:460-4. 2003
    ..to describe the daily activities of older patients as they undergo chemotherapy for incurable metastatic lung cancer...
  44. ncbi request reprint Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients
    Marie Christine Aubry
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Chest 131:1635-43. 2007
    ..The clinical significance of multiple carcinoid tumorlets in surgical lung specimens has not been systematically analyzed. We reviewed our experience to determine the range of clinical circumstances associated with this finding...
  45. ncbi request reprint A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials
    Mashele M Huschka
    Division of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:787-95. 2007
    ....
  46. ncbi request reprint Thoracic surgical operations in patients enrolled in a computed tomographic screening trial
    Juan A Crestanello
    Division of General Thoracic Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Thorac Cardiovasc Surg 128:254-9. 2004
    ..We reviewed the thoracic surgical operations performed on patients enrolled in our computed tomographic screening program...
  47. ncbi request reprint A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1)
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 52:371-81. 2002
    ....
  48. ncbi request reprint Screening for non-small cell lung cancer
    Rendell W Ashton
    Pulmonary Medicine and Medical Oncology, Mayo College of Medicine, 200 1st St SW, Rochester, MN 55905, USA
    Semin Oncol 32:253-8. 2005
    ..Patients who are interested in being screened for lung cancer should be encouraged to participate in well-designed clinical trials whenever possible...
  49. doi request reprint Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis
    Rajesh R Patel
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:917-22. 2008
    ..To determine the value of positron emission tomography (PET) in diagnosing occult malignancies in patients with paraneoplastic neurologic syndromes (PNSs) at Mayo Clinic's site in Rochester, MN...
  50. ncbi request reprint Update in lung cancer 2005
    James R Jett
    Mayo College of Medicine, Rochester, Minnesota, USA
    Am J Respir Crit Care Med 173:695-7. 2006
  51. ncbi request reprint Superior sulcus tumors and Pancoast's syndrome
    James R Jett
    Mayo Clinic, Thoracic Diseases and Medical Oncology, 200 First Street SW, Desk E18B, Rochester, MN 55905, USA
    Lung Cancer 42:S17-21. 2003
  52. ncbi request reprint Change in smoking status after spiral chest computed tomography scan screening
    Lisa Sanderson Cox
    Nicotine Research Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 98:2495-501. 2003
    ..The current study evaluated smoking behavior changes in current and former smokers after low-dose, fast spiral chest computed tomography scan (CT) screening for lung carcinoma...
  53. ncbi request reprint Computed tomographic screening for lung cancer: home run or foul ball?
    Stephen J Swensen
    Department of Radiology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:1187-8. 2003
  54. ncbi request reprint Screening for lung cancer with low-dose spiral computed tomography
    Stephen J Swensen
    Department of Radiology, The Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Respir Crit Care Med 165:508-13. 2002
    ..Twelve (57%) of the 21 non-small cell cancers detected by computed tomography were stage IA at diagnosis. Computed tomography can detect early-stage lung cancers. The rate of benign nodule detection is high...
  55. doi request reprint Update on screening for lung cancer
    David E Midthun
    Mayo Clinic, Rochester, MN 55905, USA
    Semin Respir Crit Care Med 29:233-40. 2008
    ..This review examines the problem presented by lung cancer, the issues presented by screening, and the results of past and recent studies of lung cancer screening...
  56. ncbi request reprint Small cell lung cancer: current therapy and promising new regimens
    Scott H Okuno
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Oncologist 7:234-8. 2002
    ..In this review, we cover current therapy and promising new regimens and highlight areas where improvement is needed in the management of small cell lung cancer...
  57. ncbi request reprint A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients
    Aminah Jatoi
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 12:859-63. 2004
    ..The safety and pharmacokinetics of infliximab in combination with docetaxel, a commonly used chemotherapy agent for non-small-cell lung cancer, were explored in this pilot study...
  58. ncbi request reprint Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group?
    Thomas V Colby
    Department of Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Cancer 95:2361-5. 2002
    ....
  59. ncbi request reprint Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
    Elizabeth A Johnson
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Lung Cancer 60:200-7. 2008
    ....
  60. ncbi request reprint Invasive and noninvasive advances in the staging of lung cancer
    Fabien Maldonado
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN Electronic address
    Semin Oncol 41:17-27. 2014
    ..The necessary multidisciplinary approach to lung cancer patients dictates that all stakeholders be familiar with the benefits and limitations of these newer techniques. ..
  61. ncbi request reprint Glomus tumor of the trachea: value of multidetector computed tomographic virtual bronchoscopy
    Hassan F Nadrous
    Division of Pulmonary and Critical Care Medicine and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:237-40. 2004
    ..The patient was disease-free 3 months postoperatively. To our knowledge, this is the first reported case in which additional computed postprocessing was used to help evaluate the extent of such a tumor...
  62. ncbi request reprint How to optimize staging in early non-small cell lung cancer
    James R Jett
    Thoracic Diseases and Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Lung Cancer 38:S13-6. 2002
  63. doi request reprint Screening for lung cancer: the US studies
    David E Midthun
    Mayo Clinic, Rochester, Minnesota
    J Surg Oncol 108:275-9. 2013
    ..This review examines the results of past and recent studies of lung cancer screening...
  64. ncbi request reprint A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens
    Kevin C Halling
    Department of Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Chest 130:694-701. 2006
    ..To determine the relative sensitivity and specificity of cytology and fluorescence in situ hybridization (FISH) for the detection of lung cancer in bronchoscopically obtained specimens...
  65. ncbi request reprint Does interstitial lung disease predispose to lung cancer?
    Craig E Daniels
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Pulm Med 11:431-7. 2005
    ..This review examines the evidence for the causality and pathogenesis of lung cancer associated with interstitial lung disease...
  66. ncbi request reprint Screening for lung cancer: no longer a taboo subject
    James R Jett
    J Clin Oncol 20:1959-61. 2002
  67. ncbi request reprint Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society
    Heber Macmahon
    Radiology 237:395-400. 2005
    ....
  68. pmc Using protein microarray as a diagnostic assay for non-small cell lung cancer
    Li Zhong
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kentucky, Chandler Medical Center, K528 Kentucky Clinic, 740 S Limestone, Lexington, Kentucky 40536, USA
    Am J Respir Crit Care Med 172:1308-14. 2005
    ..Phenotypic and genotypic heterogeneity of lung cancer likely precludes the identification of a single predictive marker and suggests the importance of identifying and measuring multiple markers...
  69. ncbi request reprint Lung cancer screening results: easily misunderstood
    David E Midthun
    Mayo Clin Proc 82:14-5. 2007
  70. ncbi request reprint Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement
    Thomas J Lynch
    Division of Hematology Oncology and Dana Farber Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Clin Cancer Res 11:4981s-4983s. 2005
  71. ncbi request reprint Computed tomography screening and lung cancer outcomes
    Peter B Bach
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 297:953-61. 2007
    ..Randomized controlled trials assessing CT screening are currently under way...
  72. ncbi request reprint Profiling tumor-associated antibodies for early detection of non-small cell lung cancer
    Li Zhong
    Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Kentucky, Lexington, KY 40536, USA
    J Thorac Oncol 1:513-9. 2006
    ..A blood test for non-small cell lung cancer (NSCLC) may be a valuable tool for use in a comprehensive lung cancer screening strategy. Here we report the potential of autoantibody profiling to detect early-stage and occult NSCLC...
  73. ncbi request reprint Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference
    Gary M Strauss
    Division of Medical Oncology, Rhode Island Hospital, Brown Medical School, 593 Eddy St, Providence, RI 02903, USA
    Chest 127:1146-51. 2005
    ..The Como Conference was undertaken to consider the need for a change in the existing recommendations against screening...
  74. ncbi request reprint Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 13:2684-91. 2007
    ..To evaluate the combination of sorafenib and gefitinib in patients with advanced non-small cell lung cancer...
  75. ncbi request reprint Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    Peter B Bach
    Memorial Sloan Kettering Cancer Center, 307 East 63rd St, Third Floor, New York, NY 10021, USA
    Chest 132:69S-77S. 2007
    ..Because early-stage disease can be successfully treated, a screening technique that can detect lung cancer before it has spread might be useful in decreasing lung cancer mortality...
  76. ncbi request reprint Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma
    Louise Burke
    Department of Pathology, Cork University Hospital, Cork, Ireland
    Clin Cancer Res 11:232-41. 2005
    ..We hypothesize that cumulative abnormalities within each and between these pathways would have significant prognostic potential regarding survival...